|
|
|
| Effects of quality of life in patients with intermediate and advanced lung cancer undergoing different treatment regimens |
| WANG Yue1, HUANG Xiaotong2, ZHAO Fei1, Ding Lili1, WU Bingyi1
|
1. School of Management, Shandong Second Medical University, Weifang, Shandong 261053, China;
2. School of Nursing, Shandong Second Medical University, Weifang, Shandong 261053, China |
|
|
|
|
Abstract Objective To examine the impacts of chemotherapy/radiotherapy, targeted therapy, and combined treatment on the quality of life in patients with intermediate and advanced lung cancer. Methods The patients with intermediate and advanced lung cancer undergoing chemotherapy/radiotherapy, targeted therapy, and combined treatment for the first time were recruited from a tertiary hospital in Weifang City, Shandong Province, using a quota sampling method in September 2023. Basic information was collected using a general information questionnaire, and the quality of life was assessed using the Chinese version of Functional Assessment of Cancer Therapy-General. The investigation started on the 7th day of treatment, and the follow-ups were conducted at 3 and 6 months. The quality of life in patients with different treatment regimens and at different treatment time were compared using repeated measure analysis of variance. Results There were 26 chemotherapy/radiotherapy patients, 32 targeted therapy patients, and 95 combination therapy patients. There were no significant differences in age, gender, place of residence, education level, self-rated economic status, medical insurance, pathological type and disease stage among the three treatment regimens (all P>0.05). The repeated measure analysis of variance showed an interaction effect between time and group among patients receiving the three treatment regimens (P<0.05). The quality of life scores of patients receiving combination therapy decreased with extended treatment time (all P<0.05). The quality of life scores of patients receiving targeted therapy at 3 and 6 months were lower than those treated for 7 days (both P<0.05). No significant differences were observed in quality of life scores among chemotherapy/radiotherapy patients with different treatment durations (all P>0.05). At 3 and 6 months, patients receiving combination therapy had lower quality of life scores compared to those receiving chemotherapy/radiotherapy or targeted therapy (all P<0.05). Conclusion The decline in quality of life for patients with intermediate and advanced lung cancer undergoing chemotherapy/radiotherapy and targeted therapy is less than that for patients receiving combined therapy.
|
|
Received: 05 September 2024
Revised: 17 February 2025
Published: 17 March 2025
|
|
|
|
|
|
[1] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[2] KARANIKAS M,ESEMPIDIS A,CHASAN Z T,et al.Pancreatic cancer from molecular pathways to treatment opinion[J].J Cancer,2016,7(10):1328-1339.
[3] CHOU H L,CHAO T Y,CHEN T C,et al.The relationship between inflammatory biomarkers and symptom distress in lung cancer patients undergoing chemotherapy[J].Cancer Nurs,2017,40(2):1-8.
[4] 高月霞,徐程,刘国恩,等.社会支持对老年人健康相关生命质量影响研究——基于南通的实证[J].人口与发展,2013,19(4):73-81.
GAO Y X,XU C,LIU G E,et al.Social support and health related quality of life of the elderly:evidence from Nantong[J].Popul Dev,2013,19(4):73-81.(in Chinese)
[5] YUAN T,ZHOU Y,WANG T,et al.Impact research of pain nursing combined with hospice care on quality of life for patients with advanced lung cancer[J].Medicine(Baltimore),2024,103(22):1-8.
[6] 中华医学会肿瘤学分会.中华医学会肺癌临床诊疗指南(2024版)[J].中华肿瘤杂志,2024,46(9):805-843.
Oncology Society of Chinese Medical Association.Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer(2024 edition)[J].Chin J Oncol,2024,46(9):805-843.(in Chinese)
[7] TRAVIS W D,BRAMBILLA E,NICHOLSON A G,et al.The 2015 World Health Organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J].J Thorac Oncol,2015,10(9):1243-1260.
[8] 万崇华,孟琼,汤学良,等.癌症患者生命质量测定量表FACT-G中文版评介[J].实用肿瘤杂志,2006,21(1):77-80.
WAN C H,MENG Q,TANG X L,et al.A review of the Chinese version of the Functional Assessment of Cancer Therapy-General(FACT-G)[J].J Prac Oncol,2006,21(1):77-80.(in Chinese)
[9] 杨鹏. 靶向药物的研究进展与开发前沿[J].药学进展,2020,44(9):641-643.
YANG P.Research progress and development frontier of targeting drugs[J].Prog Pharm Sci,2020,44(9):641-643.(in Chinese)
[10] 伍志新. 晚期肺癌患者靶向药物治疗的应用及对生命质量影响评估[J].中国农村卫生,2021,13(15):30-31.
WU Z X.Application of targeted drug therapy in patients with advanced lung cancer and assessment of its impact on quality of life[J].China Rural Health,2021,13(15):30-31.(in Chinese)
[11] 刘卓环,罗美华,邹爱梅,等.靶向药物对EGFR基因突变的晚期肺癌患者生命质量的影响分析[J].中国实用医药,2020,15(33):99-101.
LIU Z H,LUO M H,ZOU A M,et al.Effect of targeted drugs on the quality of life of advanced lung cancer patients with EGFR gene mutation[J].China Prac Med,2020,15(33):99-101.(in Chinese)
[12] 杨海玉,郭娇,孙元明,等.放射性脑损伤机制与防治方法研究进展[J].辐射防护,2020,40(4):346-352.
YANG H Y,GUO J,SUN Y M,et al.Review on the mechanism,prevention and treatments of radiation brain injury[J].Radiat Prot,2020,40(4):346-352.(in Chinese)
[13] 白美蓉,张爱华.肺癌患者心理状态、支持性照护需求与生存质量的关系研究[J].当代护士(下旬刊),2023,30(7):95-101.
BAI M R,ZHANG A H.A study of the relationship between psychological status,supportive care needs and quality of survival in lung cancer patients[J].Mod Nurse,2023,30(7):95-101.(in Chinese) |
| [1] |
QIU Fengqian, ZHAO Junfeng, CHEN Weihua, DU Juan, JI Yunfang, GAO Shuna, MENG Jie, HE Lihua, CHEN Bo, ZHANG Yan. Trends in incidence and mortality of lung cancer in Huangpu District from 2002 to 2019[J]. Preventive Medicine, 2025, 37(2): 143-147. |
|
|
|
|
